Clinical trial
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
NCT00445003 · Jaeb Center for Health Research, Other · Completed
Key facts
| NCT number | NCT00445003 |
|---|---|
| Title | Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy |
| Official title | Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy |
| Acronym | LRTforDME+PRP |
| Lead sponsor | Jaeb Center for Health Research, Other |
| Collaborators | National Eye Institute (NEI) NIH Genentech, Inc. Industry Allergan |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Proliferative Diabetic Retinopathy, Diabetic Macular Edema |
| Intervention type | Behavioral, Drug, Procedure |
| Interventions | Ranibizumab, Triamcinolone Acetonide, Sham injection, Focal/grid laser |
| Enrollment | 333 |
| Start date | Mar 1, 2007 |
| Primary completion | Oct 1, 2009 |
| Completion | Jul 1, 2010 |
| First posted | Mar 8, 2007 |
| Last update posted | Aug 26, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: